The aim of our project is to exploit miRNAs as drugs or targets in innovative therapeutic strategies for CLL (chronic lymphocytic leukemia) and MM (multiple myeloma) based on biologically driven hypothesis, novel in vitro and in vivo preclinical models and innovative delivery nanotechnologies.
Finanziamenti AIRC e FIRC 2011 Grazie alla generosità dei loro interlocutori, soci, volontari, contribuenti, sostenitori e al supporto dei mezzi di comunicazione, nel 2011 AIRC e FIRC hanno deliberato la somma totale di 99.379.940 euro. FIRC …
I tuoi momenti di gioia lo saranno anche per la ricerca. Sono diverse le occasioni in cui puoi sostenere il lavoro dei ricercatori: scegli le bomboniere solidali AIRC per il tuo matrimonio, oppure per festeggiare …
The research team will provide technological and intellectual support in different phases of the research program and in all planned Tasks.
MicroRNAs (miRNAs) are a class of small non-coding RNAs which regulate gene expression at the post-transcriptional level. As a result of imperfect complementarity with target mRNAs, they may cause repression of translation or mRNA degradation. More than 700 miRNAs have been identified which can modulate tens or hundreds of gene targets.
miRNAs are conceivably important modulators of cellular pathways and may play a key role in tumorigenesis; indeed their expression is aberrant in many malignant cells where in some cases they appear to act as oncogenes while in others as tumor suppressor genes1.
Recent data have associated aberrant miRNA expression to prognosis and therapeutical response. Finally, modulation of miRNA activities provides opportunities for cancer therapy since miRNAs can regulate tumor cell growth, survival and chemosensitivity.